Liminatus Pharma, Inc. Class A Common Stock cash flow to debt ratio of -690.70% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Liminatus Pharma, Inc. Class A Common Stock's free cash flow has decreased 221.15% from $-3.11M last year to $-9.98M, signaling decreasing performance

Liminatus Pharma, Inc. Class A Common Stock's debt to equity ratio is -10.88, signaling that the company spent its equity and risk bankruptcy.

Liminatus Pharma, Inc. Class A Common Stock's debt to equity ratio is -10.88, signaling that the company spent its equity and risk bankruptcy.

Liminatus Pharma, Inc. Class A Common Stock has negative EBITDA, making leverage ratio unreliable

Liminatus Pharma, Inc. Class A Common Stock's interest coverage ratio is -31.96, which means that the company struggles to meet interest obligations, signaling financial risk.

Liminatus Pharma, Inc. Class A Common Stock has insufficient data to evaluate this check.

Liminatus Pharma, Inc. Class A Common Stock's short-term liabilities of $10.30M exceed its short-term assets of $500.57K, signaling financial risk

Liminatus Pharma, Inc. Class A Common Stock's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Liminatus Pharma, Inc. Class A Common Stock's return on equity of 215.73%, is higher than 15.00%, indicating good performance

Liminatus Pharma, Inc. Class A Common Stock's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Liminatus Pharma, Inc. Class A Common Stock has insufficient public price history to evaluate earnings stability.

Liminatus Pharma, Inc. Class A Common Stock has negative free cash flow, indicating the company is burning cash rather than generating it

Liminatus Pharma, Inc. Class A Common Stock has negative free cash flow, indicating cash burn

Liminatus Pharma, Inc. Class A Common Stock's yearly earnings has decreased 251.43% since last year from $-2.90M to $-10.21M, signaling decreasing performance

Liminatus Pharma, Inc. Class A Common Stock's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -283.21% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Liminatus Pharma, Inc. Class A Common Stock has insufficient revenue history to calculate 3-year revenue CAGR.

Liminatus Pharma, Inc. Class A Common Stock has insufficient public price history to evaluate revenue consistency.

Liminatus Pharma, Inc. Class A Common Stock has insufficient public price history to evaluate ROE consistency.

Liminatus Pharma, Inc. Class A Common Stock has insufficient data to evaluate this check.

Liminatus Pharma, Inc. Class A Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Liminatus Pharma, Inc. Class A Common Stock is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Liminatus Pharma, Inc. Class A Common Stock has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Liminatus Pharma, Inc. Class A Common Stock has insufficient data to evaluate this check.

Liminatus Pharma, Inc. Class A Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Liminatus Pharma, Inc. Class A Common Stock has negative shareholder equity; price-to-book is not meaningful and the check fails

Liminatus Pharma, Inc. Class A Common Stock has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue